Novocure Must Show Its Breakout Second Quarter Was A Trend, Not A One-Off

Novocure heads into its third-quarter report with an awkward contradiction. Management has raised its full-year revenue outlook at every call this year, turned adjusted EBITDA positive for the first time since 2024, and pulled its breakeven target forward a full year. Yet the stock has fallen 12.7% since the last report while the S&P 500 gained 4%. That gap suggests the market is not yet convinced the second quarter's strength can be repeated, and the October 29 release is the first real chance to settle the question.

The Street is not asking for much on the surface. Consensus calls for a loss of $0.21 per share on revenue of $183.3 million. That would be a 36% improvement from last year's $0.33 loss and revenue growth of about 9.6%, solid but well short of the 16% pace posted in the second quarter. Notably, the revenue estimate is essentially flat with the $183.6 million just reported, while the expected loss is wider than the prior quarter's $0.13. Part of that is reasonable caution: the second quarter benefited from a $5 million tariff refund and about $3 million of one-time items, and the finance chief warned that the top of the raised range implies some moderation after an exceptional quarter.

The guidance math frames the bar. Novocure now expects 2026 revenue of $710 million to $725 million, up from $690 million to $710 million, and full-year consensus of $712.4 million sits near the low end. With roughly $358 million booked in the first half, the range implies about $176 million to $184 million per quarter for the rest of the year. A third quarter at or above consensus would put the company on track for the upper half of its range and keep the pattern of raises alive. A print in the mid-$170 millions would technically fit the outlook but would revive doubts that the second quarter was inflated.

The operating details matter more than the headline numbers. The core OptuneGeo brain cancer franchise re-accelerated last quarter, with U.S. active patients up 8% after periods of flat to low single-digit growth, and total actives of 4,636 up 11%. Sustaining that U.S. rate is the single best evidence that the base business is healthy. The newer OptunePax pancreatic launch is the growth story: prescriptions jumped to 418 in its first full quarter and active patients reached 285. The key tell is whether repeat prescribing improves, since about half of prescribers had written only one script. Early contributions from the German Pax launch and the Japan OptuneLua rollout would support the raised $20 million to $30 million combined Lua and Pax revenue target, though both face slow, case-by-case reimbursement and hospital contracting.

On profitability, gross margin of 78% was flattered by the tariff refund, so a figure that holds in the mid-to-high 70s on array cost improvements would be encouraging. R&D should keep drifting lower as the redesigned LUNAR-2 lung trial sheds roughly $90 million of planned spend. Updates on the fourth-quarter FDA decision for Optune Maya in lung cancer brain metastases and on potential industry partners for a RAS-inhibitor combination trial could also shape the outlook.

Sentiment has cooled modestly, with readings slipping to 11.8% bearish from 8.4%. The stock, at $15.71, sits above its 200-day average of $14.80 but in the lower half of its post-earnings range of $13.76 to $21.45, well off the highs reached after the last report. That leaves room for a rebound if the numbers cooperate. Ultimately, the report hinges on whether Novocure can hold revenue near second-quarter levels while staying on course for positive adjusted EBITDA. If it does, the skeptics pricing in a one-quarter wonder will have a harder argument to make.

This earnings preview was originally published on Earnings Whispers.

This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It was generated automatically, with the help of AI, from Earnings Whispers and company data, and checked by Earnings Whispers before publication.